Home > Healthcare > Medical Devices > Diagnostic Devices > ivd in cardiology and neurology market
Get a free sample of IVD in Cardiology and Neurology Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of IVD in Cardiology and Neurology Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The IVD in cardiology and neurology industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
Some of the eminent market participants operating in the IVD in cardiology and neurology industry include:
Abbott Laboratories, Becton, Dickinson, and Company, bioMerieux S.A., Bio-Rad Laboratories, Inc., Danaher Corporation, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific Inc.
North America held 40.8% of the IVD in cardiology and neurology industry share in 2023, and will witness significant growth till 2032, due to presence of well-established healthcare infrastructure, advanced diagnostic technologies, and a strong emphasis on R&D in the field of medicine.
The reagents, kits, & consumables product type segment is estimated to record USD 12 billion by the end of 2032, owing to higher adoption in diagnostic testing for cardiovascular and neurological disorders.
IVD in cardiology and neurology industry size was USD 15.6 billion in 2023 and is estimated to exceed USD 24 billion by 2032, due to increasing incidence and prevalence of cardiovascular diseases (CVDs) and neurological disorders like Alzheimer's disease, Parkinson's disease, and stroke.